Pulmonary arterial hypertension (PAH) is a highly morbid disease, characterized by progressive pulmonary vascular remodeling and obliteration and a significant increase in pulmonary vascular resistance and pulmonary arterial pressure. PAH patients often require heart and lung transplantation to survive; current treatment options are not curative or capable of stopping or reversing disease progress. Poor understanding of the molecular origins of PAH and diagnoses in late stages of the disease contribute to the ineffectiveness of treatment. There is an urgent clinical need to develop effective therapeutic approaches and non-invasive means of diagnosis and risk prediction.
Sun, W., Tang, Y., Tai, Y.-Y., Handen, A., Zhao, J., Speyer, G., Al Aaraj, Y., Watson, A., Romanelli, M. E., Sembrat, J., Rojas, M., Simon, M. A., Zhang, Y., Lee, J., Xiong, Z., Dutta, P., Vasamsetti, S. B., McNamara, D., McVerry, B., … Chan, S. Y. (2020). SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function. JACC: Basic to Translational Science, 5(11), 1073–1092. https://doi.org/10.1016/j.jacbts.2020.08.010